ZA201304481B - Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate - Google Patents

Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Info

Publication number
ZA201304481B
ZA201304481B ZA2013/04481A ZA201304481A ZA201304481B ZA 201304481 B ZA201304481 B ZA 201304481B ZA 2013/04481 A ZA2013/04481 A ZA 2013/04481A ZA 201304481 A ZA201304481 A ZA 201304481A ZA 201304481 B ZA201304481 B ZA 201304481B
Authority
ZA
South Africa
Prior art keywords
therapeutic compositions
tenofovir disoproxil
disoproxil fumarate
rilpivirine hcl
rilpivirine
Prior art date
Application number
ZA2013/04481A
Other languages
English (en)
Inventor
Reza Oliyai
Mark M Menning
Lauren Wiser
Original Assignee
Gilead Sciences Inc
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201304481(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen R&D Ireland filed Critical Gilead Sciences Inc
Publication of ZA201304481B publication Critical patent/ZA201304481B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2013/04481A 2010-11-19 2013-06-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate ZA201304481B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Publications (1)

Publication Number Publication Date
ZA201304481B true ZA201304481B (en) 2022-03-30

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04481A ZA201304481B (en) 2010-11-19 2013-06-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Country Status (36)

Country Link
US (1) US10857102B2 (https=)
EP (2) EP2826466A1 (https=)
JP (2) JP2014500261A (https=)
KR (1) KR101923103B1 (https=)
CN (2) CN103491948B (https=)
AP (1) AP3816A (https=)
AR (2) AR084500A1 (https=)
AU (3) AU2011329642B2 (https=)
BR (1) BR112013012245B1 (https=)
CA (1) CA2818097C (https=)
CL (1) CL2013001402A1 (https=)
CO (1) CO6761300A2 (https=)
CR (1) CR20130293A (https=)
DK (1) DK2640362T4 (https=)
EA (2) EA201691695A1 (https=)
EC (2) ECSP13012700A (https=)
ES (1) ES2524408T5 (https=)
HK (1) HK1206592A1 (https=)
HR (1) HRP20140946T1 (https=)
IL (1) IL226300B (https=)
MA (1) MA34735B1 (https=)
ME (1) ME01980B (https=)
MX (1) MX347512B (https=)
MY (1) MY185604A (https=)
NZ (1) NZ610729A (https=)
PE (3) PE20211657A1 (https=)
PH (1) PH12013501002A1 (https=)
PL (1) PL2640362T5 (https=)
PT (1) PT2640362E (https=)
RS (1) RS53691B1 (https=)
SG (3) SG190333A1 (https=)
SM (1) SMT201400150B (https=)
TW (1) TWI556840B (https=)
UA (1) UA114075C2 (https=)
WO (1) WO2012068535A1 (https=)
ZA (1) ZA201304481B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ, インコーポレイテッド リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
WO2015014737A1 (en) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3439639A1 (en) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるhivを治療する方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0514871A (pt) 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2006304180A1 (en) 2005-10-14 2007-04-26 Microdose Therapeutx, Inc. Pharmaceutical packaging of an oral dosage combination
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2393485B1 (en) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
CN102596958A (zh) 2009-09-21 2012-07-18 吉里德科学公司 用于抗病毒治疗的2’-氟代carba-核苷类似物
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ, インコーポレイテッド リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Also Published As

Publication number Publication date
SMT201400150B (it) 2015-01-15
MA34735B1 (fr) 2013-12-03
AU2016208417A1 (en) 2016-08-18
JP2015131853A (ja) 2015-07-23
PT2640362E (pt) 2014-11-28
AU2016208417B2 (en) 2018-04-05
DK2640362T3 (en) 2014-12-01
PE20211657A1 (es) 2021-08-24
SG10201912527XA (en) 2020-02-27
ME01980B (me) 2015-05-20
PE20170521A1 (es) 2017-05-27
CN103491948B (zh) 2016-11-02
EA201691695A1 (ru) 2017-11-30
CL2013001402A1 (es) 2013-12-27
KR20140037799A (ko) 2014-03-27
PE20140163A1 (es) 2014-02-08
EP2640362B1 (en) 2014-09-10
IL226300B (en) 2019-05-30
NZ610729A (en) 2015-10-30
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
EA025852B1 (ru) 2017-02-28
MX347512B (es) 2017-04-28
UA114075C2 (xx) 2017-04-25
SG190333A1 (en) 2013-06-28
AU2011329642A1 (en) 2013-05-02
CA2818097C (en) 2019-07-30
CA2818097A1 (en) 2012-05-24
AU2018202635A1 (en) 2018-05-10
SG10201509521WA (en) 2015-12-30
CR20130293A (es) 2013-10-03
US20130243857A1 (en) 2013-09-19
CN103491948A (zh) 2014-01-01
HRP20140946T1 (hr) 2015-02-13
ES2524408T3 (es) 2014-12-09
TW201238612A (en) 2012-10-01
EA201390651A1 (ru) 2013-11-29
JP6138851B2 (ja) 2017-05-31
BR112013012245A2 (pt) 2016-08-09
EP2640362B2 (en) 2021-12-01
EP2826466A1 (en) 2015-01-21
MY185604A (en) 2021-05-25
US10857102B2 (en) 2020-12-08
CO6761300A2 (es) 2013-09-30
EP2640362A1 (en) 2013-09-25
MX2013005669A (es) 2013-11-04
PL2640362T5 (pl) 2022-05-02
KR101923103B1 (ko) 2018-11-28
HK1206592A1 (en) 2016-01-15
AP2013006931A0 (en) 2013-06-30
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
BR112013012245B1 (pt) 2022-09-27
RS53691B1 (sr) 2015-04-30
AR123409A2 (es) 2022-11-30
PH12013501002A1 (en) 2013-09-09
AP3816A (en) 2016-09-30
HK1190064A1 (en) 2014-06-27
PL2640362T3 (pl) 2015-03-31
TWI556840B (zh) 2016-11-11
ECSP13012700A (es) 2013-08-30
WO2012068535A1 (en) 2012-05-24
JP2014500261A (ja) 2014-01-09
AR084500A1 (es) 2013-05-22
ES2524408T5 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
AP3816A (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP2646468A4 (en) ANTI-NGF COMPOSITIONS AND THEIR USE
ZA201404099B (en) Human notch receptor mutations and their use
ZA201300286B (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfactase and uses thereof
SMT202100448T1 (it) Formulazione di impianto di risperidone e/o paliperidone
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
ZA201403372B (en) Therapeutic agents and uses thereof
SG10201606161UA (en) Albumin Formulation and Use
EP2643000A4 (en) THERAPEUTIC PIPERAZINES
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
IL239424A0 (en) Oral care products containing tetrabasic zinc chloride and trimethylglycine
PT2521445T (pt) Formulação e utilização da mesma
GB201011411D0 (en) Therapeutic compounds and their use
PT2563806E (pt) Leucolectinas humanas e suas utilizações
IL236548A0 (en) Preparations containing phosphonate esters of tanafovir and their uses
IL238461A0 (en) 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors
SI2640362T2 (sl) Terapevtski sestavki, ki vsebujejo rilpivirin hcl in tenovofir disoproksil
IL229936B (en) Albumin formulation and use
AU332227S (en) Therapeutic pillow
GB201012660D0 (en) Inhaler and formulation
GB201209296D0 (en) 'Flip and Walk'
GB201003741D0 (en) Methods and therapeutic compositions
GB201006380D0 (en) Excipients and their use